Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants From Rsv Disease During Their First Rsv Season
默沙东宣布FDA接受其生物制品许可申请,Clesrovimab是一种研究中的长效单克隆抗体,旨在保护婴儿在他们的第一个RSV季节中免受RSV疾病的影响